2022 Fiscal Year Final Research Report
Optimization of organoid culture system based on histology and driver mutations in lung cancer
Project/Area Number |
20K17765
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 55040:Respiratory surgery-related
|
Research Institution | Kawasaki Medical School |
Principal Investigator |
|
Project Period (FY) |
2020-04-01 – 2023-03-31
|
Keywords | 肺癌 / オルガノイド / 個別化医療 |
Outline of Final Research Achievements |
Recently, organoids derived from various cancers have been established and used as new cancer models to replace cell lines and genetically engineered mice in cancer research. In this study, we focused on histological differences and driver mutations of lung cancer, and optimized the organoid culture system. Normal organoids originating from normal lung epithelial cells reportedly proliferate faster and get replaced by cancer cells during the generation of lung cancer organoids, which is considered as one of the reasons for the failure of the establishment. By examining culture conditions for each histological type of lung cancer, we established an organoid culture system in an MDM2 inhibitor-free media, making it theoretically possible to establish organoids from a p53 wild-type lung cancer.
|
Free Research Field |
呼吸器外科
|
Academic Significance and Societal Importance of the Research Achievements |
臨床病期Ⅰ期、Ⅱ期の非小細胞肺癌の根治術後、26%に局所や遠隔再発がみられている(Boyd et al. J Thorac Oncol 5: 210-4. 2010)。このような再発症例や、ドライバー変異不明肺癌から、オルガノイドを作製し、in vitroでの薬剤感受性試験を行うことで治療効果を予測できるようになる。オルガノイドが樹立法の改善は、個別化医療の進展や新規治療法開発のための基礎研究に寄与する。
|